299 related articles for article (PubMed ID: 25980436)
1. SMYD3 contributes to a more aggressive phenotype of prostate cancer and targets Cyclin D2 through H4K20me3.
Vieira FQ; Costa-Pinheiro P; Almeida-Rios D; Graça I; Monteiro-Reis S; Simões-Sousa S; Carneiro I; Sousa EJ; Godinho MI; Baltazar F; Henrique R; Jerónimo C
Oncotarget; 2015 May; 6(15):13644-57. PubMed ID: 25980436
[TBL] [Abstract][Full Text] [Related]
2. Deregulated expression of selected histone methylases and demethylases in prostate carcinoma.
Vieira FQ; Costa-Pinheiro P; Ramalho-Carvalho J; Pereira A; Menezes FD; Antunes L; Carneiro I; Oliveira J; Henrique R; Jerónimo C
Endocr Relat Cancer; 2014 Feb; 21(1):51-61. PubMed ID: 24200674
[TBL] [Abstract][Full Text] [Related]
3. SMYD3 as an oncogenic driver in prostate cancer by stimulation of androgen receptor transcription.
Liu C; Wang C; Wang K; Liu L; Shen Q; Yan K; Sun X; Chen J; Liu J; Ren H; Liu H; Xu Z; Hu S; Xu D; Fan Y
J Natl Cancer Inst; 2013 Nov; 105(22):1719-28. PubMed ID: 24174655
[TBL] [Abstract][Full Text] [Related]
4. The telomerase reverse transcriptase (hTERT) gene is a direct target of the histone methyltransferase SMYD3.
Liu C; Fang X; Ge Z; Jalink M; Kyo S; Björkholm M; Gruber A; Sjöberg J; Xu D
Cancer Res; 2007 Mar; 67(6):2626-31. PubMed ID: 17363582
[TBL] [Abstract][Full Text] [Related]
5. Histone methyltransferase PRMT6 plays an oncogenic role of in prostate cancer.
Almeida-Rios D; Graça I; Vieira FQ; Ramalho-Carvalho J; Pereira-Silva E; Martins AT; Oliveira J; Gonçalves CS; Costa BM; Henrique R; Jerónimo C
Oncotarget; 2016 Aug; 7(33):53018-53028. PubMed ID: 27323813
[TBL] [Abstract][Full Text] [Related]
6. The SMYD3-MAP3K2 signaling axis promotes tumor aggressiveness and metastasis in prostate cancer.
Ikram S; Rege A; Negesse MY; Casanova AG; Reynoird N; Green EM
Sci Adv; 2023 Nov; 9(46):eadi5921. PubMed ID: 37976356
[TBL] [Abstract][Full Text] [Related]
7. Valproic acid inhibits the proliferation of cancer cells by re-expressing cyclin D2.
Witt D; Burfeind P; von Hardenberg S; Opitz L; Salinas-Riester G; Bremmer F; Schweyer S; Thelen P; Neesen J; Kaulfuss S
Carcinogenesis; 2013 May; 34(5):1115-24. PubMed ID: 23349020
[TBL] [Abstract][Full Text] [Related]
8. Novobiocin decreases SMYD3 expression and inhibits the migration of MDA-MB-231 human breast cancer cells.
Luo XG; Zou JN; Wang SZ; Zhang TC; Xi T
IUBMB Life; 2010 Mar; 62(3):194-9. PubMed ID: 20039369
[TBL] [Abstract][Full Text] [Related]
9. SET and MYND domain-containing protein 3 decreases sensitivity to dexamethasone and stimulates cell adhesion and migration in NIH3T3 cells.
Luo XG; Ding Y; Zhou QF; Ye L; Wang SZ; Xi T
J Biosci Bioeng; 2007 May; 103(5):444-50. PubMed ID: 17609160
[TBL] [Abstract][Full Text] [Related]
10. SMYD3 encodes a histone methyltransferase involved in the proliferation of cancer cells.
Hamamoto R; Furukawa Y; Morita M; Iimura Y; Silva FP; Li M; Yagyu R; Nakamura Y
Nat Cell Biol; 2004 Aug; 6(8):731-40. PubMed ID: 15235609
[TBL] [Abstract][Full Text] [Related]
11. The lysine 831 of vascular endothelial growth factor receptor 1 is a novel target of methylation by SMYD3.
Kunizaki M; Hamamoto R; Silva FP; Yamaguchi K; Nagayasu T; Shibuya M; Nakamura Y; Furukawa Y
Cancer Res; 2007 Nov; 67(22):10759-65. PubMed ID: 18006819
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of SMYD3 in Ovarian Cancer is Associated with Ovarian Cancer Proliferation and Apoptosis via Methylating H3K4 and H4K20.
Jiang Y; Lyu T; Che X; Jia N; Li Q; Feng W
J Cancer; 2019; 10(17):4072-4084. PubMed ID: 31417652
[No Abstract] [Full Text] [Related]
13. Upregulated SMYD3 promotes bladder cancer progression by targeting BCLAF1 and activating autophagy.
Shen B; Tan M; Mu X; Qin Y; Zhang F; Liu Y; Fan Y
Tumour Biol; 2016 Jun; 37(6):7371-81. PubMed ID: 26676636
[TBL] [Abstract][Full Text] [Related]
14. SET and MYND domain-containing protein 3 is overexpressed in human glioma and contributes to tumorigenicity.
Dai B; Wan W; Zhang P; Zhang Y; Pan C; Meng G; Xiao X; Wu Z; Jia W; Zhang J; Zhang L
Oncol Rep; 2015 Nov; 34(5):2722-30. PubMed ID: 26328527
[TBL] [Abstract][Full Text] [Related]
15. High immunoexpression of Ki67, EZH2, and SMYD3 in diagnostic prostate biopsies independently predicts outcome in patients with prostate cancer.
Lobo J; Rodrigues Â; Antunes L; Graça I; Ramalho-Carvalho J; Vieira FQ; Martins AT; Oliveira J; Jerónimo C; Henrique R
Urol Oncol; 2018 Apr; 36(4):161.e7-161.e17. PubMed ID: 29174711
[TBL] [Abstract][Full Text] [Related]
16. Targeting INMT and interrupting its methylation pathway for the treatment of castration resistant prostate cancer.
Zhong S; Jeong JH; Huang C; Chen X; Dickinson SI; Dhillon J; Yang L; Luo JL
J Exp Clin Cancer Res; 2021 Sep; 40(1):307. PubMed ID: 34587977
[TBL] [Abstract][Full Text] [Related]
17. SMYD3 associates with the NuRD (MTA1/2) complex to regulate transcription and promote proliferation and invasiveness in hepatocellular carcinoma cells.
Yang Y; Qiu R; Zhao S; Shen L; Tang B; Weng Q; Xu Z; Zheng L; Chen W; Shu G; Wang Y; Zhao Z; Chen M; Ji J
BMC Biol; 2022 Dec; 20(1):294. PubMed ID: 36575438
[TBL] [Abstract][Full Text] [Related]
18. Therapeutical potential of deregulated lysine methyltransferase SMYD3 as a safe target for novel anticancer agents.
Rajajeyabalachandran G; Kumar S; Murugesan T; Ekambaram S; Padmavathy R; Jegatheesan SK; Mullangi R; Rajagopal S
Expert Opin Ther Targets; 2017 Feb; 21(2):145-157. PubMed ID: 28019723
[TBL] [Abstract][Full Text] [Related]
19. Knockdown of SMYD3 by RNA interference down-regulates c-Met expression and inhibits cells migration and invasion induced by HGF.
Zou JN; Wang SZ; Yang JS; Luo XG; Xie JH; Xi T
Cancer Lett; 2009 Jul; 280(1):78-85. PubMed ID: 19321255
[TBL] [Abstract][Full Text] [Related]
20. Restoration of cyclin D2 has an inhibitory potential on the proliferation of LNCaP cells.
Kobayashi T; Nakamura E; Shimizu Y; Terada N; Maeno A; Kobori G; Kamba T; Kamoto T; Ogawa O; Inoue T
Biochem Biophys Res Commun; 2009 Sep; 387(1):196-201. PubMed ID: 19577536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
